European Journal of Biomedical and Pharmaceutical Sciences

A RECENT ADVANCEMENT AND TREATMENT OVERVIEW OF DEPRESSION

Subhanshu Katiyar*, Deepak Shukla and Ashish Srivastava

ABSTRACT

Depression and depressive symptoms are common mental disorders that have a considerable effect on patients’ health-related quality of life and satisfaction with medical care, but the prevalence of these conditions varies substantially between published studies. The purpose of this research is to carry out a comprehensive review and meta-analysis so that an accurate estimate of the number of outpatients suffering from depression or depressed symptoms may be obtained across a variety of clinical subspecialties. This review Mainly focus at the research on desvenlafaxine's usage in MDD therapy. In adults, desvenlafaxine was a successful antidepressant with good safety and tolerability. The subset of peri- and postmenopausal women with MDD showed efficacy, but not children and adolescents. Due to its metabolic nature, there is a relatively minimal risk for drug-drug interactions. While severe renal failure necessitates certain dose changes, hepatic impairment does not dramatically change dosage needs. Patients with concomitant physical ailments may benefit from desvenlafaxine. When treating MDD clients without other medical comorbidities, desvenlafaxine may be a first option. Despite the fact that these hit molecules are readily available, around 30% of depressive patients do not react to the current pharmacological regimens, and the remaining 70% do not have a full remission. Antidepressants can have a wide range of adverse effects including drug-drug and drug-food interactions. To develop more effective and secure medications to treat serious depression, various ways are being tested in this situation. One such chemical that has shown encouraging effectiveness in several animal models of severe depression is curcumin. Curcumin's antidepressant effect is thought to work by blocking the monoamine oxidase enzyme and controlling the release of serotonin and dopamine, while the exact mechanism of action is still unclear. This review examines the pharmacology and molecular mechanisms of curcumin's antidepressant impact in animal models of depression. Curcumin's antidepressant effectiveness and safety require clinical testing.

Keywords: MDD (Major depressive disorder).